HLX43 for advanced nasopharyngeal cancer after prior treatments
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal cancer that has come back or spread to other parts of the body.
- You have already tried at least two different types of chemotherapy (including one with platinum) and a PD-1/PD-L1 immunotherapy drug, and either your cancer did not respond or you could not tolerate the side effects.
- You have at least one tumor that can be measured on a scan.
- You are willing to provide a tumor sample (from a past biopsy or a new one) for testing.
- You are age 18 or older and your overall health is good enough to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests an experimental drug called HLX43, given alone or with other immune-boosting drugs, for people with advanced triple-negative breast cancer (a type of breast cancer that does not have the common hormone receptors). The goal is to see if this drug can shrink tumors or slow cancer growth.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.